Article info

Extended report
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Authors

  1. Correspondence to Dr Christopher J Edwards, University Hospital Southampton NHS Foundation Trust, Mailpoint 218, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK; cedwards{at}soton.ac.uk.
View Full Text

Citation

Edwards CJ, Blanco FJ, Crowley J, et al
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Publication history

  • Received May 21, 2015
  • Revised November 30, 2015
  • Accepted December 12, 2015
  • First published January 20, 2016.
Online issue publication 
May 10, 2016

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.